Comparative study of quality of life in breast cancer patients receiving two different chemotherapy regimens using European Organization for Research and Treatment of Cancer Quality of Questionnaire-Core 30 questionnaire module; for tolerability and safety

Naveen Chauhan; Kiran Haridas; Indrani Poddar; Krishna Prasad; M. C. Alwar; Dinesh Pai Kasturi

doi:10.18203/2319-2003.ijbcp20150369

Authors

Naveen Chauhan Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India
Kiran Haridas Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India
Indrani Poddar Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India
Krishna Prasad Department of Medical Oncology, Kasturba Medical College, Mangalore, Karnataka, India
M. C. Alwar Department of Pharmacology, Kasturba Medical College, Mangalore, Karnataka, India
Dinesh Pai Kasturi Department of Oncology and Radiotherapy, Kasturba Medical College, Mangalore, Karnataka, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20150369

Keywords:

Breast cancer, Health-related quality of life, 5-Fluorouracil, Adriamycin, Cyclophosphamide, Paclitaxel

Abstract

Background: Breast cancer is one of the most frequent occurring cancers in women and burgeoning worldwide. It is the second most common malignancy in India after carcinoma of the uterine cervix. In clinical trials, quality of life (QOL) outcome measurements is an important as endpoints with improving subjects physical, emotional, and social well-being.

Methods: In this study, we were evaluated the comparison of the QOL in breast cancer patients on anthracycline-based regimen (six cycles of 5-fluorouracil, adriamycin, and cyclophosphamide [FAC] for a period of 18 weeks) and taxane-containing regimen (four cycles of adriamycin and cyclophosphamide [AC] followed by four cycles of paclitaxel [PTX] for a period of 24 weeks) using European Organization for Research and Treatment of Cancer Quality of Questionnaire-Core 30.

Results: During first 3 months of therapy, both treatment groups exhibited a reduction in health-related QOL (HRQOL) with no clinically significant difference between them. The effect on HRQOL was less evident 3 weeks after completing chemotherapy with HRQOL of both groups returning to near baseline scores.

Conclusions: Both treatment regimens (FAC and AC → PTX [AC followed by PTX]) were equally tolerated in patients.

Metrics

Metrics Loading ...

References

Siddiqui F, Kachnic LA, Movsas B. Quality-of-life outcomes in oncology. Hematol Oncol Clin North Am. 2006;20(1):165-85.

Parkin DM. Global cancer statistics in the year 2000. Lancet Oncol. 2001;2(9):533-43.

Paymaster JC. Cancer of the breast in Indian women. Surgery. 1956;40:372-7.

McPhee SJ, Papadakis MA, Tierney LM. Breast. In: Current Medical Diagnosis and Treatment. 47th Edition. New York, NY: McGraw-Hill; 2008.

Slevin ML, Plant H, Lynch D, Drinkwater J, Gregory WM. Who should measure quality of life, the doctor or the patient? Br J Cancer. 1988;57(1):109-12.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European organization for research and treatment of cancer QLQ-c30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85(5):365-76.

Sweetman SC. In: Martindale Complete Drug Reference. 35th Edition. London, UK: Pharmaceutical Press; 2007.

Nowak AK, Wilcken NR, Stockler MR, Hamilton A, Ghersi D. Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer. Lancet Oncol. 2004;5(6):372-80.

Mamounas EP, Bryant J, Lembersky B, Fehrenbacher L, Sedlacek SM, Fisher B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol. 2005;23(16):3686-96.

Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A. On behalf of the EORTC quality of life group. The EORTC QLQ-C30 Scoring Manual. 3rd Edition. Brussels: European Organisation for Research and Treatment of Cancer; 2001.

Osoba D. Rationale for the timing of health-related quality-of-life (HQL) assessments in oncological palliative therapy. Cancer Treat Rev. 1996;22 Suppl A:69-73.

Kenney LB, Yasui Y, Inskip PD, Hammond S, Neglia JP, Mertens AC, et al. Breast cancer after childhood cancer: a report from the childhood cancer survivor study. Ann Intern Med. 2004;141(8):590-7.

Friedman DL, Rovo A, Leisenring W, Locasciulli A, Flowers ME, Tichelli A, et al. Increased risk of breast cancer among survivors of allogeneic hematopoietic cell transplantation: a report from the FHCRC and the EBMT-late effect working party. Blood. 2008;111(2):939-44.

Smith-Warner SA, Spiegelman D, Yaun SS, van den Brandt PA, Folsom AR, Goldbohm RA, et al. Alcohol and breast cancer in women: a pooled analysis of cohort studies. JAMA. 1998;279(7):535-40.

Hamajima N, Hirose K, Tajima K, Rohan T, Calle EE, Heath CW Jr, et al. Alcohol, tobacco and breast cancer – collaborative reanalysis of individual data from 53 epidemiological studies, including 58,515 women with breast cancer and 95,067 women without the disease. Br J Cancer. 2002;87(11):1234-45.

Degnim AC, Visscher DW, Berman HK, Frost MH, Sellers TA, Vierkant RA, et al. Stratification of breast cancer risk in women with atypia: a mayo cohort study. J Clin Oncol. 2007;25(19):2671-7.

Brunton LL, Lazo JS, Parker KL. Antineoplastic agents. In: Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 11th Edition. New York, NY: McGraw-Hill; 2006.

Bottomley A, Therasse P, Piccart M, Efficace F, Coens C, Gotay C, et al. Health-related quality of life in survivors of locally advanced breast cancer: an International Randomised Controlled Phase III Trial. Lancet Oncol. 2005;6(5):287-94.

Martín M, Lluch A, Seguí MA, Ruiz A, Ramos M, Adrover E, et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen. Ann Oncol. 2006;17(8):1205-12.